4 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.5%) at 15,564 as of Friday, Sept. 20, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 854 issues advancing vs. 2,087 declining with 92 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 0.9%, and Valeant Pharmaceuticals International ( VRX), down 0.9%. Top gainers within the industry include Allergan ( AGN), up 1.7%, Shire ( SHPG), up 1.1%, Alexion Pharmaceuticals ( ALXN), up 1.1%, GlaxoSmithKline ( GSK), up 0.7% and Sanofi ( SNY), up 0.7%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Ariad Pharmaceuticals ( ARIA) is one of the companies pushing the Drugs industry lower today. As of noon trading, Ariad Pharmaceuticals is down $1.02 (-4.8%) to $20.47 on average volume. Thus far, 1.0 million shares of Ariad Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $20.43-$21.47 after having opened the day at $21.46 as compared to the previous trading day's close of $21.49.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector. Shares are up 8.8% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Ariad Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Ariad Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Questcor Pharmaceuticals ( QCOR) is down $4.20 (-6.9%) to $56.48 on heavy volume. Thus far, 4.9 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $54.36-$61.78 after having opened the day at $61.50 as compared to the previous trading day's close of $60.68.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector. Shares are up 145.6% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Questcor Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Herbalife ( HLF) is down $2.08 (-2.8%) to $71.38 on average volume. Thus far, 1.5 million shares of Herbalife exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $70.80-$73.60 after having opened the day at $73.30 as compared to the previous trading day's close of $73.46.

Herbalife Ltd., through its subsidiaries, produces and distributes weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $7.6 billion and is part of the consumer goods sector. Shares are up 122.5% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Herbalife a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.67 (-1.4%) to $46.86 on average volume. Thus far, 4.8 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $46.67-$47.59 after having opened the day at $47.56 as compared to the previous trading day's close of $47.53.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $74.7 billion and is part of the health care sector. Shares are up 42.7% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

OPEC, Bank Stress Tests, Disney and Tesla - 5 Things You Must Know

OPEC, Bank Stress Tests, Disney and Tesla - 5 Things You Must Know

Big Banks Pass the Stress Tests and 4 Other Stories to Watch Friday Morning

Big Banks Pass the Stress Tests and 4 Other Stories to Watch Friday Morning

OPEC Debating 1 Million Barrel Oil Market Boost as Iran Signals Support

OPEC Debating 1 Million Barrel Oil Market Boost as Iran Signals Support

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'